A
Amicogen
Innovative biocatalysts and proteins for health and environmental sustainability
About Amicogen
Amicogen, a leading industrial biotechnology company based in Korea, specializes in developing innovative biocatalysts and proteins using proprietary iDNA technology. The company operates in the healthcare, nutrition, and biopharmaceutical sectors, serving clients ranging from healthcare providers to nutrition companies. Amicogen's business model revolves around the research, development, and commercialization of bio-products and new bio-ingredients aimed at improving human health and preserving the environment. Revenue is generated through the sale of these specialized products and through strategic investments and partnerships, including supply agreements and convertible bond takeovers. The company has a strong presence in both local and international markets, including China, and continues to expand its manufacturing capabilities. Amicogen's commitment to innovation and sustainability positions it as a key player in the biotechnology industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- South Korea
- Listing
- IPO 2013
- Sector
- Health
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- CPCompany K Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amicogen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amicogen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.